Bevacizumab plus Atezolizumab — Competitive Intelligence Brief

Bevacizumab plus Atezolizumab (Bevacizumab plus Atezolizumab) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anti-angiogenic agent and PD-L1 inhibitor. Area: Oncology.

phase 2 Anti-angiogenic agent and PD-L1 inhibitor VEGF-A and PD-L1 Oncology Small molecule

Target snapshot

Bevacizumab plus Atezolizumab (Bevacizumab plus Atezolizumab) — Ze-yang Ding, MD. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), while atezolizumab is a monoclonal antibody that inhibits programmed death-ligand 1 (PD-L1), thereby enhancing anti-tumor immune response.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bevacizumab plus Atezolizumab TARGET	Bevacizumab plus Atezolizumab	Ze-yang Ding, MD	phase 2	Anti-angiogenic agent and PD-L1 inhibitor	VEGF-A and PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anti-angiogenic agent and PD-L1 inhibitor class)

1. Ze-yang Ding, MD · 1 drug in this class